Elpida®: innovations in HIV treatment in Russia
On October 5, 2017 in St. Petersburg as part of the Second Forum on HIV, the Viriom company of ChemRar Group conducts a scientific symposium “Innovations in HIV treatment in Russia”, dedicated to the first Russian innovative drug in the 21st century for first-line HIV treatment — ELPIDA® (elsulfavirin).
The Viriom symposium will be held on the opening day of the Forum, chaired by the Chief Specialist of the St. Petersburg Health Committee on the problems of diagnosis and treatment of HIV infection, The Chief Physician of the St. Petersburg Centre for the Prevention and Control of AIDS and Infectious Diseases, Professor D.A. Gusev and Professor A.V. Kravchenko, Doctor of Medial Sciences, the Chief Research Officer at the Central Research Institute of Epidemiology of Rospotrebnadzor (Moscow). The Symposium will present data on the drug, including the results of the Russian multicenter comparative clinical trial of ELPIDA® conducted in 12 clinical centers over 48 weeks.
The speakers of the Symposium program with reports on HIV treatment and the trial results will be Professor A.V. Kravchenko; G.A. Efimov, researcher at the St. Petersburg Centre for Prevention and Control of AIDS and Infectious Diseases; F.I. Nagimova, Deputy Chief Physician of the Republican Center for the Prevention and Control of AIDS and Infectious Diseases of the Republic of Tatarstan (Kazan), as well as members of the Scientific Advisory Board of Viriom — Milos Petrovic and Janet Hammond, who will present the history of creation and potential of the new molecule.
The Forum will be attended by 500 delegates from all regions of Russia — experts in the field of HIV treatment, heads of the regional centers for AIDS and infectious disease treatment.
ELPIDA® (elsulfavirin) is a new-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) (Registration Certificate No. LP-004360 of June 30, 2017).
ELPIDA® was developed by Viriom in partnership with F. Hoffmann-La Roche (Switzerland) and with the support of the Russian Ministry of Industry and Trade within the Federal Targeted Program “Development of Pharmaceutical and Medical Industry of the Russian Federation for up to 2020 and Beyond” (“Pharma-2020”) and the Skolkovo Foundation.
Viriom is a company at ChemRar High-Tech Center, involved in the development of innovative drugs for HIV, hepatitis C and influenza treatment. Viriom, oriented toward top world standards, aimed at improvement of treatment outcomes and patients’ quality of life, improvement of access to treatment for all patients who need it, reduction of the burden and fully curing socially significant infections.